Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models

被引:16
作者
Labaune, JM
Bleyzac, N [1 ]
Maire, P
Jelliffe, RW
Boutroy, MJ
Aulagner, G
Putet, G
机构
[1] Debrousse Hosp, Dept Pharm, 29 Rue Soeur Bouvier, F-69005 Lyon, France
[2] Univ Lyon 1, Debrousse Hosp, Dept Neonatol, F-69365 Lyon, France
[3] A Charial Hosp, ADCAPT, Francheville, France
[4] Univ So Calif, Lab Appl Pharmacokinet, Los Angeles, CA USA
[5] H Poincare Univ, INSERM 272 Lab, Nancy, France
来源
BIOLOGY OF THE NEONATE | 2001年 / 80卷 / 02期
关键词
amikacin; newborn; population pharmacokinetics;
D O I
10.1159/000047133
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Amikacin is widely used in the treatment of suspected or confirmed neonatal infections. However, dosage regimens are not well defined in this group of patients because of a wide inter-individual pharmacokinetic variability. An individualized goal-oriented amikacin dosage design was applied using population pharmacokinetic data. A dosing chart was developed for neonates during the first 2 days of life, by using population pharmacokinetic parameter values and USCPACK software. This dosing chart based on gestational age (GA) and body weight gives a once-a-day amikacin dosage regimen involving an injection every 24 h. Validation was performed in 57 neonates less than 2 days old, divided into three GA groups and prospectively treated using the dosing chart. Target peak serum levels of amikacin were obtained in 62-80% of patients after the first dose and in 80-100% after the second dose, and trough concentrations were obtained in 100%. This study has confirmed the need for individualization of amikacin dosage regimens in neonates. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 21 条
[1]   ESTIMATING GLOMERULAR-FILTRATION RATE IN INFANTS [J].
ARANT, BS .
JOURNAL OF PEDIATRICS, 1984, 104 (06) :890-893
[2]   A SUGGESTED APPROACH TO ONCE-DAILY AMINOGLYCOSIDE DOSING [J].
BEGG, EJ ;
BARCLAY, ML ;
DUFFULL, SB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) :605-609
[3]  
BLEYZAC N, 1997, 37 INT C ANT AG CHEM
[4]   PREDICTION OF FUTURE SERUM CONCENTRATIONS WITH BAYESIAN FITTED PHARMACOKINETIC MODELS - RESULTS WITH DATA COLLECTED BY NURSES VERSUS TRAINED PHARMACY RESIDENTS [J].
CHARPIAT, B ;
BREANT, V ;
PIVOTDUMAREST, C ;
MAIRE, P ;
JELLIFFE, R .
THERAPEUTIC DRUG MONITORING, 1994, 16 (02) :166-173
[5]  
dYvoire HJYB, 1996, CLIN DRUG INVEST, V11, P229
[6]   Antibacterial therapy in pregnancy and neonates [J].
Edwards, MS .
CLINICS IN PERINATOLOGY, 1997, 24 (01) :251-+
[7]   INDIVIDUALIZING DRUG-DOSAGE REGIMENS - ROLES OF POPULATION PHARMACOKINETIC AND DYNAMIC-MODELS, BAYESIAN FITTING, AND ADAPTIVE-CONTROL [J].
JELLIFFE, RW ;
SCHUMITZKY, A ;
VANGUILDER, M ;
LIU, M ;
HU, L ;
MAIRE, P ;
GOMIS, P ;
BARBAUT, X ;
TAHANI, B .
THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :380-393
[8]   AMIKACIN PHARMACOKINETICS AND SUGGESTED DOSAGE MODIFICATIONS FOR THE PRETERM INFANT [J].
KENYON, CF ;
KNOPPERT, DC ;
LEE, SK ;
VANDENBERGHE, HM ;
CHANCE, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :265-268
[9]  
*LAB APPL PHARM, 1995, USCASTERISKPACK PC C
[10]  
Labaune JM., 1996, ARCH PEDIATR, V3, P1297